ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance

Metastatic pancreatic cancer (PC) is an aggressive malignancy, with most patients deriving benefit only from first-line chemotherapy. Increasingly, the recommended treatment for those with a germline mutation in a gene involved in homologous recombination repair is with a platinum drug followed by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martino, Candice, Pandya, Deep, Lee, Ronald, Levy, Gillian, Lo, Tammy, Lobo, Sandra, Frank, Richard C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946099/
https://www.ncbi.nlm.nih.gov/pubmed/31856090
http://dx.doi.org/10.1097/MPA.0000000000001461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946099/
https://www.ncbi.nlm.nih.gov/pubmed/31856090
http://dx.doi.org/10.1097/MPA.0000000000001461

Ejemplares similares